1887
Rapid communication Open Access
Like 0

Abstract

To update information on the epidemiological situation and national capacity for detection, surveillance and containment of carbapenem-resistant (CRAb) in Europe, we performed a survey in 37 countries. Nine countries reported regional or inter-regional spread and seven an endemic situation. Laboratories with a reference function, surveillance systems, and a national containment plan for CRAb existed in 30, 23 and eight countries, respectively. A pan-European molecular survey would provide in-depth understanding of the CRAb epidemiology.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.45.2001735
2020-11-12
2024-12-18
/content/10.2807/1560-7917.ES.2020.25.45.2001735
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/45/eurosurv-25-45-3.html?itemId=/content/10.2807/1560-7917.ES.2020.25.45.2001735&mimeType=html&fmt=ahah

References

  1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82.  https://doi.org/10.1128/CMR.00058-07  PMID: 18625687 
  2. European Centre for Disease Prevention and Control (ECDC). Carbapenemase-producing bacteria in Europe - Interim results from the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project 2013. Stockholm: ECDC; 2013. Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/antimicrobial-resistance-carbapenemase-producing-bacteria-europe.pdf
  3. Brolund A, Lagerqvist N, Byfors S, Struelens MJ, Monnet DL, Albiger B, et al. . Worsening epidemiological situation of carbapenemase-producing Enterobacteriaceae in Europe, assessment by national experts from 37 countries, July 2018. Euro Surveill. 2019;24(9):1900123.  https://doi.org/10.2807/1560-7917.ES.2019.24.9.1900123  PMID: 30862330 
  4. Marí-Almirall M, Cosgaya C, Higgins PG, Van Assche A, Telli M, Huys G, et al. MALDI-TOF/MS identification of species from the Acinetobacter baumannii (Ab) group revisited: inclusion of the novel A. seifertii and A. dijkshoorniae species. Clin Microbiol Infect. 2017;23(3):210.e1-9.  https://doi.org/10.1016/j.cmi.2016.11.020  PMID: 27919649 
  5. European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings. Stockholm: ECDC; 2016. Available from: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/8-Dec-2016-RRA-Acinetobacter%20baumannii-Europe.pdf
  6. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. , Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19(1):56-66.  https://doi.org/10.1016/S1473-3099(18)30605-4  PMID: 30409683 
  7. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2019. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/surveillance-antimicrobial-resistance-Europe-2018.pdf
  8. Strateva T, Sirakov I, Stoeva T, Stratev A, Dimov S, Savov E, et al. Carbapenem-resistant Acinetobacter baumannii: Current status of the problem in four Bulgarian university hospitals (2014-2016). J Glob Antimicrob Resist. 2019;16:266-73.  https://doi.org/10.1016/j.jgar.2018.10.027  PMID: 30412782 
  9. Munier AL, Biard L, Legrand M, Rousseau C, Lafaurie M, Donay JL, et al. Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit. Int J Infect Dis. 2019;79:179-84.  https://doi.org/10.1016/j.ijid.2018.11.371  PMID: 30529108 
  10. Venditti C, Vulcano A, D’Arezzo S, Gruber CEM, Selleri M, Antonini M, et al. Epidemiological investigation of an Acinetobacter baumannii outbreak using core genome multilocus sequence typing. J Glob Antimicrob Resist. 2019;17:245-9.  https://doi.org/10.1016/j.jgar.2018.11.027  PMID: 30553929 
  11. Potron A, Bour M, Triponney P, Muller J, Koebel C, A. Bonnin R, et al. Sequential emergence of colistin and rifampicin resistance in an OXA-72- producing outbreak strain of Acinetobacter baumannii. Int J Antimicrob Agents. 2019;53(5):669-73.  https://doi.org/10.1016/j.ijantimicag.2019.01.012  PMID: 30685310 
  12. Eigenbrod T, Reuter S, Gross A, Kocer K, Günther F, Zimmermann S, et al. Molecular characterization of carbapenem-resistant Acinetobacter baumannii using WGS revealed missed transmission events in Germany from 2012-15. J Antimicrob Chemother. 2019;74(12):3473-80.  https://doi.org/10.1093/jac/dkz360  PMID: 31504593 
  13. Valencia-Martín R, Gonzalez-Galan V, Alvarez-Marín R, Cazalla-Foncueva AM, Aldabó T, Gil-Navarro MV, et al. , In representation of A. baumannii eradication program. A multimodal intervention program to control a long-term Acinetobacter baumannii endemic in a tertiary care hospital. Antimicrob Resist Infect Control. 2019;8(1):199.  https://doi.org/10.1186/s13756-019-0658-4  PMID: 31827780 
  14. Metan G, Zarakolu P, Otlu B, Tekin I, Aytac H, Bolek EC, et al. Emergence of colistin and carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii (CCR-Acb) complex in a neurological intensive care unit followed by successful control of the outbreak. J Infect Public Health. 2020;13(4):564-70.  https://doi.org/10.1016/j.jiph.2019.09.013  PMID: 31672426 
  15. Molter G, Seifert H, Mandraka F, Kasper G, Weidmann B, Hornei B, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii in the intensive care unit: a multi-level strategic management approach. J Hosp Infect. 2016;92(2):194-8.  https://doi.org/10.1016/j.jhin.2015.11.007  PMID: 26778130 
  16. World Health Organization Regional Office for Europe (WHO/Europe). Central Asian and Eastern European Surveillance of Antimicrobial Resistance, Annual Report for 2019. Copenhagen: WHO/Europe; 2019. Available from: http://www.euro.who.int/__data/assets/pdf_file/0003/418863/53373-WHO-CAESAR-annual-report-2019.pdf
/content/10.2807/1560-7917.ES.2020.25.45.2001735
Loading

Data & Media loading...

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error